KEIO RESEARCHERS INFORMATION SYSTEM

Profile 【 Display / hide 】

Profile 【 Display / hide 】

• 学　歴
  1995年（平成7年）3月 北海道大学医学部卒業（医学士）
  1999年（平成11年）3月 北海道大学大学院医学研究科　病理系専攻医学博士課程修了、学位取得（博士（医学））
  2002年（平成14年）3月　～　2004年（平成16年）7月
  Molecular pharmacology at University of California, San Diego, Department of Pharmacology (Dr. Paul A. Insel; as a research fellow)
  
  職　歴
  1999年（平成11年）4月 北海道大学医学部附属病院　病理部　（医員）
  2000年（平成12年）4月 北海道大学大学院医学研究科　分子細胞病理学　（助手）
  2008年（平成20年）10月 北海道大学大学院医学研究科　探索病理学講座　（特任准教授）
  2012年（平成24年）11月 北海道大学病院臨床研究開発センター　生体試料管理室　（室長（兼任））
  2015年（平成27年）1月 北海道大学大学院医学研究科探索病理学講座　（特任教授）
  2016年（平成28年）4月 北海道大学病院がん遺伝子診断部　（統括マネージャー（兼任））
  2017年（平成29年）4月 国立病院機構　北海道がんセンター　がんゲノム医療センター（センター長）
  北海道大学病院　がん遺伝子診断部　客員教授（兼任；2018年3月まで）
  札幌医科大学医学部　客員教授（兼任；2019年3月まで）
  　　　　 長崎大学医学部　客員教授（兼任）
  2017年（平成29年）7月 慶應義塾大学医学部　客員教授（兼任）　腫瘍センターゲノム医療ユニット　　
  2017年（平成29年）11月 慶應義塾大学医学部　特任教授　腫瘍センターゲノム医療ユニット長
  社会医療法人北斗　北斗病院　病理・遺伝子診断科長（兼任）
  2018年（平成30年）10月 鹿児島大学医学部　客員教授（兼任）
  2019年（平成31年）4月　 慶應義塾大学医学部　教授　臨床研究推進センター・腫瘍センターゲノム医療ユニット
  筑波大学医学部　客員教授（兼任）
  

Academic Background 【 Display / hide 】

Academic Background 【 Display / hide 】

• 1989.04

  -

  1995.03

  Hokkaido University, 医学部, 医学科

  University, Graduated, Master's course

• 1995.04

  -

  1999.03

  Hokkaido University, 大学院, 医学研究科

  Graduate School, Completed, Doctoral course

Academic Degrees 【 Display / hide 】

Academic Degrees 【 Display / hide 】

• 博士（医学）, Hokkaido University, Coursework, 1999.03

Licenses and Qualifications 【 Display / hide 】

Licenses and Qualifications 【 Display / hide 】

• 医師, 医師, 1995.04

Books 【 Display / hide 】

Books 【 Display / hide 】

• がんゲノム医療時代の分子腫瘍学

  西原, 広史, 文光堂, 2022.04,  Page： vii, 412p

• がんゲノム病理学

  田中, 伸哉, 西原, 広史, 文光堂, 2021.11,  Page： vii, 225p

• がんゲノム医療の最前線

  矢冨, 裕, 深川, 雅史, 滝川, 一, 武藤, 学, 宮地, 勇人, 西尾, 和人, 小川, 誠司, 西原, 広史, 秋田, 弘俊, 織田, 克利, 栗原, 友, H.U.グループホールディングス,ニッセイエブロ), 2021.07,  Page： 233p

Papers 【 Display / hide 】

Papers 【 Display / hide 】

• Recommendations related to the analytical equivalence assessment of gene panel testing.

  Sumimasa Nagai, Hiroshi Nishihara, Takayoshi Suzuki, Kazuto Nishio, Hiroya Taniguchi, Katsuya Tsuchihara, Kohei Nakamura, Reika Takamatsu, Toshihide Ueno, Hiroyuki Aburatani, Takashi Kohno, Shinji Kohsaka

  Cancer science  2022.07

  　View Summary

  Advances in cancer genome care over the past few years have included the development of gene panel testing for various biomarkers. This article summarizes issues and provides recommendations related to analytical performance evaluations for new oncology gene panels. The scope of these recommendations includes comprehensive genomic profiling assays related to gene panel testing that uses histological or serum specimens to detect gene mutations. As a research project of the Japan Agency for Medical Research and Development Research on Regulatory Science of Pharmaceuticals and Medical Devices, we convened the working group committee that consisted of more than 30 experts from academia, industry, and government. We have discussed the points that should be considered to allow maximal simplification of assessments using clinical specimens in evaluating accuracy and limit of detection in equivalence and analytical performance for three years. We provide recommendations specific to each type of gene mutation as well as to reference standards or specimens used for evaluations. In addition, in order to facilitate the discussion on the analytical performance of gene panel tests by multidisciplinary tumor boards of hospitals, the present recommendations also describe the items that companies are expected to provide information on in their packaging inserts and reports, and the items that are expected to be discussed by multidisciplinary tumor boards. Our working group document will be important for participants in multidisciplinary tumor boards including medical oncologists and genome scientists, and developers of gene panels not only in Japan but also in other countries.

  • Access to Document (DOI)

• Real-world application of next-generation sequencing-based test for surgically resectable colorectal cancer in clinical practice.

  Masayo Ogiri, Ryo Seishima, Kohei Nakamura, Eriko Aimono, Shimpei Matsui, Kohei Shigeta, Tatsuyuki Chiyoda, Shigeki Tanishima, Koji Okabayashi, Hiroshi Nishihara, Yuko Kitagawa

  Future oncology (London, England)  2022.07

  　View Summary

  Aim: To evaluate the significance of next-generation sequencing-based gene panel testing in surgically resectable colorectal cancer by analyzing real-world data. Materials & methods: A total of 107 colorectal cancer patients who underwent curative surgery were included, and correlations between next-generation sequencing data and clinicopathological findings were evaluated. Results: More combination patterns in gene alteration were identified in advanced-stage tumors than in early-stage tumors. The copy number alteration count was significantly lower in right-sided colon tumors and early-stage tumors. Homologous recombination deficiency was more often identified in advanced-stage tumors, and high homologous recombination deficiency status was useful for identifying high-risk stage II tumors. Conclusion: Homologous recombination deficiency was identified as a useful result of gene panel testing with novel utility in clinical practice.

  • Access to Document (DOI)

• Hybridisation chain reaction-based visualisation and screening for lncRNA profiles in clear-cell renal-cell carcinoma.

  Ryohei Kufukihara, Nobuyuki Tanaka, Kimiharu Takamatsu, Naoya Niwa, Keishiro Fukumoto, Yota Yasumizu, Toshikazu Takeda, Kazuhiro Matsumoto, Shinya Morita, Takeo Kosaka, Eriko Aimono, Hiroshi Nishihara, Ryuichi Mizuno, Mototsugu Oya

  British journal of cancer  2022.06

  　View Summary

  BACKGROUND: Analysis of long noncoding RNA (lncRNA) localisation at both the tissue and subcellular levels can provide important insights into the cell types that are important for their function. METHODS: By applying new fluorescent in situ hybridisation technique called hybridisation chain reaction (HCR), we achieved a high-throughput lncRNA visualisation and evaluation of clinical samples. RESULTS: Assessing 1728 pairs of 16 lncRNAs and clear-cell renal-cell carcinoma (ccRCC) specimens, three lncRNAs (TUG1, HOTAIR and CDKN2B-AS1) were associated with ccRCC prognosis. Furthermore, we derived a new lncRNA risk group of ccRCC prognosis by combining the expression levels of these three lncRNAs. Examining genomic alterations underlying this classification revealed prominent features of tumours that could serve as potential biomarkers for targeting lncRNAs. We then derived combination of HCR with expansion microscopy and visualised nanoscale-resolution HCR signals in cell nuclei, uncovering intracellular colocalization of three lncRNA (TUG1, HOTAIR and CDKN2B-AS1) signals such as those located intra- or out of the nucleus or nucleolus in cancer cells. CONCLUSION: LncRNAs are expected to be desirable noncoding targets for cancer diagnosis or treatments. HCR involves plural probes consisting of small DNA oligonucleotides, clinically enabling us to detect cancerous lncRNA signals simply and rapidly at a lower cost.

  • Access to Document (DOI)

• Influence of response to prior docetaxel on sensitivity to cabazitaxel in prostate cancer patients with PTEN alterations.

  Ken Kamisawa, Takeo Kosaka, Kohei Nakamura, Yota Yasumizu, Hiroshi Hongo, Toshikazu Takeda, Kazuhiro Matsumoto, Hiroshi Nishihara, Mototsugu Oya

  Cancer science  2022.06

  　View Summary

  The purpose of this study was to investigate factors predicting the sensitivity to cabazitaxel therapy in metastatic castration-resistant prostate cancer (mCRPC) patients with phosphatase and tensin homolog deleted from chromosome 10 (PTEN) alterations. This single-institution, retrospective study included 12 mCRPC patients with PTEN alterations who had received cabazitaxel therapy. Five patients (41%) responded to cabazitaxel therapy with a prostate-specific antigen (PSA) level decline of ≥30% from baseline, and all of them had responded to prior docetaxel therapy with a PSA decline of ≥30%. None of the patients with a poor response to prior docetaxel therapy responded well to cabazitaxel therapy. Of the seven patients who did not respond to cabazitaxel and whose PSA declined from baseline was <30%, five (71%) were also refractory to prior docetaxel therapy. The PSA responses to docetaxel and cabazitaxel were significantly correlated (p = 0.027). Kaplan-Meier analysis revealed that progression-free survival (PFS) for cabazitaxel was significantly shorter for prior docetaxel nonresponders (3.3 versus 9.1 months, p = 0.028). Multivariate analysis revealed that a poor response to prior docetaxel (PSA decline < 30%) (hazard ratio [HR] = 6.382, 95% confidence interval [CI] 1.172-34.750, p = 0.032) and baseline PSA of ≥20 ng/ml (HR = 33.584, 95% CI 2.332-483.671, p = 0.010) were independent prognostic factors for PFS with cabazitaxel therapy. These results demonstrate cross-resistance between docetaxel and cabazitaxel. The response to prior docetaxel therapy can influence the sensitivity to cabazitaxel therapy in mCRPC patients with PTEN alterations.

  • Access to Document (DOI)

• A Japanese case of castration-resistant prostate cancer with BRCA2 and RB1 co-loss and TP53 mutation: a case report.

  Tomohiro Iwasawa, Takeo Kosaka, Shinya Morita, Shuji Mikami, Kohei Nakamura, Hiroshi Hongo, Hiroshi Nishihara, Mototsugu Oya

  BMC medical genomics 15 （ 1 ） 138 - 138 2022.06

  　View Summary

  BACKGROUND: Abnormalities in homologous recombination contribute to the aggressive nature of castration-resistant prostate cancer. Retinoblastoma transcriptional corepressor 1 (RB1) and breast cancer 2 (BRCA2) exist close to each other in the same chromosome, and the significance of their concurrent loss has become a hot topic in the field of cancer research. CASE PRESENTATION: A 61-year-old man presented with a chief complaint of a mass on his head and was diagnosed as multiple bone metastases from prostate cancer. He was treated with standard medication, but he died 2 years 6 months after being diagnosed with prostate cancer. Simultaneous biallelic loss of RB1 and BRCA2 as well as a truncating mutation of tumor protein p53 (TP53) were revealed by genomic analysis. CONCLUSION: To our knowledge, this is the first report of castration-resistant prostate cancer (CRPC) with BRCA2 and RB1 co-loss and TP53 mutation. To establish a treatment strategy for highly malignant cases with such multiple genetic features is important.

  • Access to Document (DOI)

display all >>

Papers, etc., Registered in KOARA 【 Display / hide 】

Papers, etc., Registered in KOARA 【 Display / hide 】

• Gene profiling for pressure ulcer

  Nishihara, Hiroshi

  科学研究費補助金研究成果報告書 2019

• Clinical sequence platform for brain tumor

  Nishihara, Hiroshi

  科学研究費補助金研究成果報告書 2019

Reviews, Commentaries, etc. 【 Display / hide 】

Reviews, Commentaries, etc. 【 Display / hide 】

• がんゲノム医療の課題の追加発言　保険診療上の課題を中心に　全国がんプロ協議会・ゲノム医療部会報告

  西原 広史

  癌と化学療法 ((株)癌と化学療法社)  49 ( 9 ) 1011 - 1013 2022.09

  ISSN  0385-0684

  　View Summary

  個々の遺伝子プロファイルに合った個別化治療を行うプレシジョンメディシン(精密医療)は、2019年6月からはFoundationOne CDx、OncoGuide NCCオンコパネルの2種類のがんゲノム検査が保険診療にて実施できるようになったのを契機に、特にがん領域において目覚ましい発展を遂げた。しかし、コンパニオン診断薬と遺伝子パネル検査の使い分けなど、臨床現場での混乱は大きく、解決すべき課題が山積している。本稿においては、そうしたがんゲノム医療の現状と課題について述べる。(著者抄録)

• cutting-edge medicine IT/AIの医療への実装 医療現場のデジタルトランスフォーメーションを目指して ビッグデータを活用したがんゲノム医療の現状

  西原 広史

  Precision Medicine ((株)北隆館)  5 ( 9 ) 777 - 780 2022.08

  ISSN  2434-3625

• パネル検査とプレシジョンメディシンの推進

  石川 麻倫, 西原 広史

  泌尿器科 ((有)科学評論社)  16 ( 2 ) 201 - 208 2022.08

  ISSN  2435-192X

• ゲノム検査が切り拓くがん個別化医療の最前線

  西原 広史

  東京都医師会雑誌 ((公社)東京都医師会)  75 ( 7 ) 633 - 641 2022.08

  ISSN  0040-8956

• がんゲノム医療の現状と今後　泌尿器科癌におけるトピックス

  西原 広史

  西日本泌尿器科 ((一社)西日本泌尿器科学会)  84 ( 6 ) 625 - 632 2022.08

  ISSN  0029-0726

  　View Summary

  個々の遺伝子プロファイルに合った個別化治療を行うプレシジョンメディシン(精密医療)は,特にがん領域において目覚ましい発展を遂げており,2019年6月からはFoundationOne CDxがんゲノムプロファイル(F-One),OncoGuide NCCオンコパネルシステム(NCCOP)の2種類のがんゲノム検査が保険診療にて実施できるようになった。さらに,これまで1遺伝子を対象に行われてきたコンパニオン診断薬(検査)も,一度に多数の遺伝子を調べられるマルチコンパニオン診断薬が登場するなど,次世代シークエンサー(next generation sequencer;NGS)を用いたゲノム検査が主流となりつつある。泌尿器科領域では,BRCA1/2遺伝子に代表される相同組換え修復(HRR)遺伝子が欠損している腫瘍に対する分子標的治療薬であるPARP阻害剤が注目されており,BRCA1/2遺伝子異常のある去勢抵抗性前立腺癌の治療薬として承認された。ただ,BRCA1/2変異に対するコンパニオン診断薬として遺伝子プロファイリング検査であるF-Oneが指定され,化学療法投薬後でなければ保険診療で利用できないなど,保険請求上での混乱や実用性における問題点が指摘され,我が国の保険診療において解決すべき課題が山積している。本稿においては,泌尿器系腫瘍におけるがんゲノム医療の現状を紹介し,解決すべき課題や今後の方向性について紹介する。(著者抄録)

display all >>

Research Projects of Competitive Funds, etc. 【 Display / hide 】

Research Projects of Competitive Funds, etc. 【 Display / hide 】

• Gene profiling for pressure ulcer

  2017.07

  -

  2020.03

  MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (B), Principal investigator

• Clinical Sequence Platform for Brain Tumor

  2017.04

  -

  2020.03

  MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), Principal investigator

Courses Taught 【 Display / hide 】

Courses Taught 【 Display / hide 】

• ADVANCED MEDICAL TECHNOLOGIES

  2022